Apply to Speak

Please contact us to nominate speakers for our programs

 China has seen vigorous growths in its drug and medical devices industry. Propelled by recent changes in regulatory and funding environments, bringing new therapeutics and technologies to the China market becomes an appealing strategy for all kinds of investors. In 2017, China joined the ICH as a full regulatory member in an effort to actively promote the timely entry of international drugs into the Chinese market, and to support the innovation and competitiveness of its domestic pharmaceutical industry. In 2018, Hong Kong cleared way for pre-revenue biotech IPOs, 4 companies already listed on HKEX by Dec, 2018. Meanwhile, NMPA (Formally CFDA) continued its initiative of drug evaluation and approval systems, including optimizing clinical trial management, accelerating the evaluation and approval for marketing authorizations, and conducting new generic consistency evaluation (GCE).  The highest level of government also carried out the “4+7” pilot drug procurement scheme, further lowered cost as well as profit margin for generic drugs.

With all these changes in the air, there are numerous opportunities as well as uncertainties for both innovators and investors. We are designing our program and inviting Key Opinion Leaders in pharma industry, pioneers in cross-border transactions, and experts in regulatory, legal and financial topics to share their experiences and expertise to all participants who want to explore opportunities with China’s emerging healthcare market.

With 5+ programs in 2019, China FocusTM Team is constantly looking for potential speakers in all areas. Please contact us to nominate speakers for our programs.  Recommend a speaker.


Katherine Andersen

Head of U.S. Life Science & Healthcare Relationship Banking, Silicon Valley Bank

Laura Benjamin

President and CEO


Wei (William) Cao

Chairman and CEO

Gracell Biotechnologies

Miguel Forte

CEO – Zelluna Immunotherapy

CCO – the International Society for Cell and Gene Therapy

Gordon Freeman

Professor of Medical Oncology

Dana-Farber Cancer Center/Harvard Medical School


Xi-Yong (Sean) Fu


Luye Boston R&D LLC


Lei (Geffrey) Gao

Executive VP/Deputy General Manager

Harbin Pharma

Jiawen Han

Head of Business Development (USA)

Qilu Pharmaceutical


Jie (Jay) Liu

Managing Director

Torreya Partners

Harvey Lodish

Founding Member and Professor

Whitehead Institute of Biomedical Research/MIT


Travis McCready

President and CEO

Massachusetts Life Sciences Center

Hua Mu

Chief Medical Officer

Simcere Pharmaceutical Group


Danhui Wang

Founding partner

Remedeca Partners LLC


Samuel Murphy

VP and Head of International BD

Salubris Pharmaceuticals

Konstantin Poukalov

Perceptive Advisors

Anna Vardanyan

Executive Director, Business Development and Alliance Management

Everest Medicines

Qingxi (Charles) Wang

Executive President of International Division and Business Development, Executive Director of the Board

CSPC Pharmaceutical Group Ltd.


Jack Wu

Head of Business Development (USA)

Adlai Nortye Biopharma


Lijun Wu


Fosun Pharma US

Haishan Xiong

Senior VP Business Development


Xiangbin (Shawn) Xu

Executive Director

Simcere Innovation, Inc.

Zengjun (Alex) Xu

Chief Scientist


Mark Young

Co-founder & Managing Partner

Bridge Point Capital

Xiangyang (Sean) Zhang


Hengrui Therapeutics